Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study

University of Chinese Academy Sciences

Status: Completed

Conditions: Breast Cancer; PI3K/AKT/mTOR Pathway Mutation; Everolimus

Treatments: Other: No intervention, it was a retrospective study.

Study type: Observational

Funder types: Other

Identifiers

NCT05054166

EVE-CWM-01

Details and patient eligibility

About

The study aimed to investigate the efficacy of the everolimus-containing chemotherapy in metastatic breast cancer patients with PI3K/AKT/mTOR mutations.14 cases of HER2- metastatic breast cancer patients with PI3K/AKT/mTOR mutations treated with everolimus-containing chemotherapy were retrospectively analyzed.The genetic profile in PI3K/AKT/mTOR pathway was studied.

Full description

The PI3K/AKT/mTOR pathway is frequently altered in breast cancer. Everolimus is a selective inhibitor of mammalian target of Rapamycin (mTOR).The benefit of everolimus in metastatic breast cancer patients with PI3K/AKT/mTOR mutations remains unclear, especially in TNBC patients. The study aimed to investigate the efficacy of the everolimus-containing chemotherapy in metastatic breast cancer patients with PI3K/AKT/mTOR mutations.

14 cases of HER2- metastatic breast cancer participants with PI3K/AKT/mTOR mutations treated with everolimus-containing chemotherapy were retrospectively analyzed.The genetic profile in PI3K/AKT/mTOR pathway was studied.

Enrollment: 14 patients

Sex: Female

Ages: 29 to 66 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients with HER2- metastatic breast cancer
2. Patients with PI3K/AKT/mTOR mutation

Exclusion criteria

1. Patients treated with endocrinotherapy and everolimus.
2. The efficacy evaluation could not be available.